Article info

Download PDFPDF

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

Authors

  • Andrew A. Davis Division of Hematology and Oncology, Department of MedicineNorthwestern University Feinberg School of Medicine Chicago IL USA Robert H. Lurie Comprehensive Cancer Center of Northwestern University Chicago IL USA PubMed articlesGoogle scholar articles
  • Vaibhav G. Patel Division of Hematology and Medical OncologyTisch Cancer Institute, Icahn School of Medicine at Mount Sinai 1 Gustave Levy Library Place 10029 New York NY USA PubMed articlesGoogle scholar articles
  1. b 212-241-6756 vaibhav.patel{at}mountsinai.org
View Full Text

Citation

Davis AA, Patel VG
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

Publication history

  • Received May 28, 2019
  • Accepted October 5, 2019
  • First published October 26, 2019.
Online issue publication 
October 26, 2019

Related Data

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.